Husni Elbahesh

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Immune Response

Metastatic Colorectal Cancer

Top Venues

Journal of virology

This page only lists publications with an associated author ORCID identifier.

Publications

Lucas Wilken, Guus F Rimmelzwaan, Husni Elbahesh
The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms. Journal of virology 98 (8) (2024)
Lucas Wilken, Guus F Rimmelzwaan, Husni Elbahesh
The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms. Journal of virology 98 (8) (2024)
Lucas Wilken, Guus F Rimmelzwaan, Husni Elbahesh
The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms. Journal of virology 98 (8) (2024)
Lucas Wilken, Guus F Rimmelzwaan, Husni Elbahesh
The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms. Journal of virology (2024)
Robert Meineke, Sonja Stelz, Maximilian Busch, Christopher Werlein, Mark Kühnel, Danny D Jonigk, Guus F Rimmelzwaan, Husni Elbahesh
FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections. Viruses 14 (9) (2022)
Melanie Ricke-Hoch, Elisabeth Stelling, Lisa Lasswitz, Antonia P Gunesch, Martina Kasten, Francisco J Zapatero-Belinchón, Graham Brogden, Gisa Gerold, Thomas Pietschmann, Virginie Montiel, Jean-Luc Balligand, Federica Facciotti, Emilio Hirsch, Thomas Gausepohl, Husni Elbahesh, Guus F Rimmelzwaan, Anne Höfer, Mark P Kühnel, Danny Jonigk, Julian Eigendorf, Uwe Tegtbur, Lena Mink, Michaela Scherr, Thomas Illig, Axel Schambach, Tobias J Pfeffer, Andres Hilfiker, Axel Haverich, Denise Hilfiker-Kleiner
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PloS one 16 (8) (2021)